Michael T. Tetzlaff MD, PhD
|
|
- Ashlie Anderson
- 5 years ago
- Views:
Transcription
1 American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification and prognosis Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department of Translational and Molecular Pathology The University of Texas MD Anderson Cancer Center Executive Officer Translational Research Program The Alliance for Clinical Trials
2 Outline 8th Edition of AJCC staging system: N-category Lymph node metastases and satellitosis: criteria for pathologic N-category Evaluating the sentinel lymph node Guidelines and pitfalls
3 T = Primary tumor Breslow (Tumor) thickness Mitotic rate (7 th Edition) Ulceration N = Regional metastasis Lymph node Microscopic (a) Macroscopic (b) Skin/subcutaneous tissue (c) In-transit metastasis/ satellites/ microsatellites TNM staging M = Distant metastasis Lymph node Skin/subcutaneous tissue Visceral metastasis Pulmonary Non-pulmonary Serum LDH Local Nodal Systemic
4 Melanoma staging N-category: number, clinical extent and satellites Clinically occult [pnxa] versus clinically evident [pnxb] Presence of a microsatellite, satellite or in-transit metastasis modifies to [pnxc]
5 N-category determined by sentinel node evaluation in most cases If all nodes node are detected microscopically, then clinically occult and [pnxa] If at least one node is detected clinically and others are detected microscopically, then [pnxb] If satellites present, then [pnxc]
6 Satellite, Microsatellite and In-transit metastases pnc Microsatellite microscopically identified deposit of tumor separated from the primary lesion by normal tissue (no intervening fibrosis or inflammation) Satellite clinically identified separate nodule of tumor separate from primary tumor < 2 cm. In-transit metastasis clinically identified nodule of tumor > 2 cm from the primary tumor between the primary tumor and regional lymph node.
7 Pitfalls of satellitosis Intravascular deposit (IHC informative) Lesion contiguous on deeper sections Incidental nevus? Mart-1/K-67 8 th Edition of the AJCC No minimum size threshold or minimum distance from the primary lesion. Microsatellites close to the primary lesion should have additional sections cut to exclude connection.
8 N-category determined by sentinel node evaluation in most cases Most lymph node metastases are detected by examination of the sentinel lymph node. Regions of skin first drain to an initial node (the sentinel node) Different regions drain to different sentinel nodes Most likely node(s) to contain metastatic disease and Gershenwald
9 Advantages of a sentinel lymph node? Minimally invasive Provides accurate staging: Identification of the critical SLN Systematic histologic and immunohistochemical assessment maximizes sensitivity More sensitively identify the target population that will benefit from adjuvant therapy Provide more rational basis for selection of therapeutic regional node dissection
10 N-category determined by sentinel node evaluation in most cases Most lymph node metastases are detected by examination of the sentinel lymph node. Sentinel lymph nodes in melanoma About 20% positive 16% initial H&E 4% additional sections/ihc <5% with extracapsular extension
11 Indications for SLN Examination Breslow 1.00 mm (+ deep margin) 0.80 mm now generally accepted Ulceration >1 mitotic figure/mm 2 In addition, high risk features (MDACC) Clark level IV Regression (particularly when extensive) Vascular invasion Satellitosis
12 Surgical Technique Injection of dye: Blue Radioactive Geiger counter (10% or x2 higher than surrounding tissue) One or several nodes and Gershenwald
13 Lymphatic Mapping: Dye and colloid Initial scan Rescan basin First SLN Additional SLN and Gershenwald
14 Sentinel lymph node processing Bisection vs. breadloafing No frozen sections: Sub-optimal morphology Loss of subcapsular region Loss of tissue Entirely submitted (minimal disease) Histologic examination (PCR?)
15 No Frozen sections Loss of subcapsular area
16 Melanoma cells or macrophages? Morphology is difficult to interpret
17 Macrophages or melanoma? Morphology is difficult to interpret HMB45
18 Sentinel lymph node evaluation
19 Subcapsular cluster of cells in the lymph node
20 Subcapsular cluster of cells in the lymph node
21 Original melanoma SLN
22 Sentinel lymph node evaluation Positive on H&E with extracapsular extension Defined as the presence of nodal metastasis extending through the lymph node capsule into adjacent tissues usually seen as microscopic extension of metastatic melanoma into the perinodal adipose tissue.
23 Sentinel lymph node evaluation Positive by IHC Pan-Melanoma (HMB-45, tyrosinase, Mart-1) HMB-45
24 SLN: Clinical significance of histologic examination why do IHC? 479 patients (1389 SLN) from 10/97-1/01 Median Breslow: 2.09 mm Initial slides: + in 14% patients After immuno/additional sections: Additional 6% patients with positive SLN Prieto and Clark. Ann Diagn Pathol, 2002
25 Sentinel lymph node evaluation Positive by IHC Metastatic melanoma Pan-Melanoma (HMB-45, tyrosinase, Mart-1) Advised to confirm with HMB-45 IHC alone
26 What is the significance of isolated cells in the SLN? Criteria for positive lymph node Any tumor deposit size Isolated tumor cell on IHC acceptable H&E confirmation no longer required Positive for at least one melanocytic marker (HMB45, Melan-A/Mart-1) Cells have malignant morphology (similar to primary tumor) and in the correct location (subcapsular versus intracapsular) No unequivocal evidence for a minimum size threshold of microscopic tumor burden that is applied to define node positive disease.
27 Immunohistochemistry: The challenge of focal positivity Pan-Melanoma (HMB-45, tyrosinase, Mart-1) Anti-HMB-45
28 Immunohistochemistry: The challenge of focal positivity Pan-Melanoma (HMB-45, tyrosinase, Mart-1) Anti-HMB-45
29 Sentinel lymph node evaluation Pitfalls of IHC Melan-A positive macrophages in SLN Advised to confirm with HMB-45 IHC alone
30 Sentinel lymph node evaluation Pitfalls of IHC Melan-A positive macrophages in SLN Advised to confirm with HMB-45 IHC alone
31 Is there a threshold: How many cells for positive SLN? 56-yo man Pigmented nodule right forearm Tattoo (American beer) Pigment bleaching Biopsy and wide local excision
32
33
34 Diagnosis Melanoma Superficial Spreading Type Clark level IV Breslow 11 mm Associated pigment (tattoo)
35 HMB45
36 Clinical Follow-Up Sentinel lymph node (1/9) Two isolated cells Completion lymphadenectomy (-) Two years later presented with widespread metastases Died shortly thereafter
37 Desmoplastic melanoma
38 SLN
39 SLN S100
40 Sentinel lymph node evaluation Pitfalls of IHC: Capsular nevus Benign melanocytes in lymph nodes Up to 20% of lymphadenectomies for melanoma More common in MM associated with nevi Capsule (rarely intraparenchymal) Biddle et al; AJSP 2003
41 Sentinel lymph node evaluation Negative by IHC: Mimics and pitfalls Capsular nevus
42 Sentinel lymph node evaluation Negative by IHC: Mimics and pitfalls Pan-Melanoma (HMB-45, tyrosinase, Mart-1) HMB-45 HMB-45
43 Intraparenchymal Capsular Nevus
44 Intraparenchymal Capsular Nevus MART1 Pan-Melanoma (HMB-45, tyrosinase, Mart-1)
45 HMB45 HMB45 Intraparenchymal Capsular Nevus
46 Ki67 (MIB1) Ki67 (MIB1) Intraparenchymal Capsular Nevus
47 Algorithm for Capsular Nevi Location Capsular Parenchymal HMB45 Ki67 HMB45 Ki67 Comparison with previous Positive Melanoma Negative Nevus
48 Prognostic significance of SLN-positivity 580 patients, SLN + in 85 pts (15%) - in 495 pts (85%) SLN status: most significant prognostic factor (disease-free and disease-specific survival), uni- and multivariate analysis Tumor thickness and ulceration in SLNnegative patients Gershenwald et al, J Clin Oncol 1999
49 Prognostic Factors Influencing Disease-Specific Survival Multiple covariate Prognostic Factor Univariate Hazard Ratio p-value Age NS - NS Sex NS - NS Axial location.03 - NS Tumor thickness < Clark level > III Ulceration < <.0001 Total Positive Nodes < or Gershenwald et al., ASCO, 2000
50 What other variables can we provide to inform prognosis? 1,417 pts (2,203 SLN), Breadloafed and examined with routine hematoxylin and eosin Entirely submitted Negative cases were examined with immunohistochemistry
51 What other variables can we provide to inform prognosis? Total number of lymph nodes Number of lymph nodes involved Size of tumor deposit (s): Largest deposit Two dimensions Addition of all deposits Location of deposit: Subcapsular/ Intraparenchymal Both Extracapsular extension
52 Measure the largest focus in two dimensions
53 Measure the largest focus in two dimensions Subcapsular Subcaps/ Intramedullary Multiple foci Extracaps extension
54 Disease-Specific Survival by SLN Status Proportion Surviving 1.0 Negative (n=1180) 0.8 Positive (n=237) Years
55 Extent of SLN burden correlates with DSS Total number of positive nodes Proportion Surviving 1.0 SLN+ patients only (n=231) 2-3 (n=86) 3+ (n=42) Log-rank: 22.7 P< Years
56 Proportion Surviving DSS by Tumor Burden: Largest Focus <=2mm (n=207) >2mm (n=115) Log-rank: 47 P< Years
57 Proportion Surviving Tumor Location in SLN drives DSS Subcapsular Intramedullary Both Sub-capsular (n=193) Intramedullary (n=31) Both (n=84) Log-rank: 47 P< Years
58 Proportion Surviving Ulceration drives DSS even among SLN Positive Patients 1.0 SLN+ patients only No Ulceration (n=205) Ulceration (n=154) Log-rank: 32.2 P< Years
59 Microscopic Tumor Burden in SLN correlates with increased risk of additional nodal disease Variable Median (mean) DSS (p-value) Number SLN metastatic foci 1.0 (2.2) SLN tumor size area (mm 2 ) 1.4 (13.3) <0.001 Largest focus in SLN (mm) 1.6 (3.0) <0.001 SLN tumor location <0.001 Subcapsular 65 Intramedullary 11 Both 24 Extracapsular extension SLN tumor burden is an important predictor of DSS in patients with microscopic nodal disease Location of metastatic deposit (subcapsular vs. parenchymal) and size of largest focus should be reported when examining SLN from patients with cutaneous melanoma
60 Proportion Surviving Microscopic Stage III Melanoma Predictive Model SLN + Patients Only (Tumor burden, Ulceration, # positive LNs) Low risk (n=126) Intermediate risk (n=105) High risk (n=91) Log-rank: 55.4 P< Years IIIA IIIB IIIC Low risk SLN focus<= 2 mm No ulceration 1-2 total LNs + Intermediate risk ulceration OR SLN focus > 2 mm High risk 3 total pos. LNs OR ulceration AND SLN focus > 2 mm
61 Polymerase Chain Reaction (PCR) evaluation of the SLN Detection of mrna associated with melanocytic differentiation: Tyrosinase gp100 (HMB45) MART1 Not testing a melanomaspecific mrna Thus, PCR does not reliably distinguish between capsular nevi and metastatic melanoma
62 PCR as a prognostic factor Because PCR does not distinguish between capsular nevi and metastatic melanoma, it has limited use in the clinical setting. Romanini et al. Ann Oncol 2005; 16: 1832 Giese et al. JID 2005; 124: 633
63 Template for reporting lymph nodes Number of lymph nodes (SLN and non-sln) Number containing metastasis Tumor location Subcapsular Intraparenchymal Tumor size Reported in mm Measured gross exam or slide Currently NOT a component of the staging system but envisioned to guide future prognostic models and possibly direct how (neo)adjuvant therapy is deployed Extracapsular extension 5.3 x 1.8 mm
64 Self-Assessment Cases 43-yo man 2.00 mm invasive ulcerated melanoma of the left shoulder HMB45
65 Your diagnosis is: 1. Capsular nevus 2. Metastatic melanoma 3. Tattoo 4. Dermatopathic lymphadenopathy
66 Your diagnosis is: 1. Capsular nevus 2. Metastatic melanoma 3. Tattoo 4. Dermatopathic lymphadenopathy
67 Self-Assessment Cases 29 F pregnant Intermediate thickness melanoma
68 MART1 MART1 and Ki67
69 Your diagnosis is: 1. Capsular nevus 2. Metastatic melanoma 3. Dermatopathic lymphadenopathy MART1 and Ki67
70 Your diagnosis is: 1. Capsular nevus 2. Metastatic melanoma 3. Dermatopathic lymphadenopathy MART1 and Ki67
71 Self-Assessment Cases 24 woman with invasive melanoma of the right foot: 1.45 mm, 3 mitotic figures/mm 2
72 HMB45
73 Your diagnosis is: 1. Capsular nevus 2. Metastatic melanoma 3. Dermatopathic lymphadenopathy HMB45
74 Your diagnosis is: 1. Capsular nevus 2. Metastatic melanoma 3. Dermatopathic lymphadenopathy HMB45
75 Thank you Victor G. Prieto MD PhD Jonathan L. Curry MD Carlos A. Torres-Cabala MD PhD Priya Nagarajan MD PhD Phyu Aung MD PhD Doina Ivan MD Jeff Gershenwald MD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationSentinel Node in Malignant Melanoma The Pathologist s Point of View
Sentinel Node in Malignant Melanoma The Pathologist s Point of View S.J. Diaz-Cano Department of Pathology, Barts and The London School of Medicine, University of London, Barts and The London NHS Trust,
More informationMichael T. Tetzlaff MD, PhD
Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department of Translational and
More informationMelanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018
Melanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018 Victor G. Prieto, MD, PhD Professor Depts. of Pathology and Dermatology University of Texas - MD Anderson Cancer Center
More informationUpdate on Merkel cell carcinoma
Merkel cell carcinoma: Diagnosis, staging, sentinel lymph node biopsy and prognostic markers Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational
More informationMerkel cell carcinoma: Diagnosis, staging, sentinel lymph node biopsy and prognostic markers
Merkel cell carcinoma: Diagnosis, staging, sentinel lymph node biopsy and prognostic markers Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationSurgery for Melanoma and What s on the Horizon
and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationMelanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors
Melanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationUpdate on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy
Update on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology,
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationPrecision Surgery for Melanoma
Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer
Pathologic Staging Updates in Breast Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationSeventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Melanoma Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationResearch Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre
Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1
More informationDr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland
Dr Rosalie Stephens Medical Oncologist Auckland City Hospital Auckland Mr Richard Martin General Surgeon Melanoma Unit Team Waitemata District Health Board Auckland 8:30-9:25 WS #99: Interactive Case Studies
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationCollaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ]
MelanomaSkin CS Tumor Size Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ] Code 000 No mass/tumor found Description 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters
More informationPrinted by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
Table of Contents NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level
More informationWhen Do I Consider Myself Cured?
The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationBiomarkers in melanoma: staging, prognosis and detection of early metastases
Review CONTENTS Staging of melanoma Prognostic biomarkers for Stage I & II melanoma Individualized prognosis for Stage I & II melanoma patients Detection of metastasis in Stage I III melanoma Expert opinion
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi c a b c d TUMOR SIZE:
More informationThere is NO single Melanoma Stain. > 6000 Mutations in Melanoma. What else can be done to discriminate atypical nevi from melanoma?
Las Vegas Fall Clinical 2016: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi a b c a b c d TUMOR SIZE: S TAGE
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationProtocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin
Protocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual
More informationSubject Index. Dry desquamation, see Skin reactions, radiotherapy
Subject Index Actinic keratosis disseminated disease 42 surgical excision 42 AIDS, see Kaposi s sarcoma Amifostine, skin reaction prophylaxis 111 Basal cell carcinoma, superficial X-ray therapy Bowen s
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationThe New AJCC: 8 th Edition and Beyond. 8th Edition AJCC Melanoma Staging System. Jeffrey E. Gershenwald, MD, FACS. AJCC Physician to Physician
AJCC Physician to Physician 8th Edition AJCC Melanoma Staging System Jeffrey E. Gershenwald, MD, FACS Dr. John M. Skibber Professor, Department of Surgical Oncology Professor, Department of Cancer Biology
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationQuantification of Melanoma Micrometastases in Sentinel Lymph Nodes Using Real-Time RT-PCR
See related Commentaries on pages vi and xiv Quantification of Melanoma Micrometastases in Sentinel Lymph Nodes Using Real-Time RT-PCR Thomas Giese, Monika Engstner,w Ulrich Mansmann,z Wolfgang Hartschuh,w
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationTumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?
Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationSavitri Krishnamurthy, MD 1
EVOLVING TRENDS IN PATHOLOGIC EVALUATION OF AXILLARY LYMPH NODES IN BREAST CANCER Savitri Krishnamurthy, M.D. Professor Department of Pathology University of Texas M. D. Anderson Cancer Center AXILLARY
More informationOriginal Articles Primary orbital melanoma in association with cellular blue nevus
Original Articles Primary orbital melanoma in association with cellular blue nevus Tarek El-Sawy, MD, PhD, a Mathieu F. Bakhoum, PhD, a Michael Tetzlaff, MD, PhD, b Qasiem J. Nasser, MD, a Victor G. Prieto,
More informationNAACCR Hospital Registry Webinar Series
NAACCR Hospital Registry Webinar Series October 4, 2007 Abstracting Melanoma Cancer Incidence and Treatment Data Image source: commons.wikimedia.org/wiki/image.melanoma.jpg Sites include Melanoma Skin
More informationIncreasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More information23/04/2015. Recent advances in Melanoma and Non Melanoma Skin Cancer
Recent advances in and Non Skin Cancer Rodney Sinclair Professor of Dermatology University of Melbourne & Epworth Hospital 86.5% increase 120% increase 37.5% increase 1 To ascertain incidence of NMSC De
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationCompleting the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017
Completing the Puzzle AJCC TNM Staging Breast Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 OBJECTIVES Understanding of Breast TNM staging Identify clinical
More informationCollaborative Staging Manual and Coding Instructions Part II: Primary Site Schema
C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2 (M-8720-8790) C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of ear and unspecified parts of face C44.4 Skin of
More informationStaging for Residents, Nurses, and Multidisciplinary Health Care Team
Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Skin Malignancies 2/4/2010 NAACCR 2009 2010 Webinar Series Questions Please use the Q&A panel to submit your questions Send questions to All Panelist Collecting Cancer Data: Skin
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More information